Skip to main content
SpringerLink
Log in

Evaluation of 18F-labeled icotinib derivatives as potential PET agents for tumor imaging

  • Published:
Journal of Radioanalytical and Nuclear Chemistry Aims and scope Submit manuscript

Abstract

In this study, three 18F-labeled crown ether fused anilinoquinazoline derivatives ([18F]11a–c) were synthesized and evaluated as potential tumor imaging probes. The biodistribution results of [18F]11b were good. Compared with [18F]-fludeoxyglucose and l-[18F]-fluoroethyltyrosine in the same animal model, [18F]11b had better tumor/brain, tumor/muscle, and tumor/blood uptake ratios. Overall, these results suggest that [18F]11b is promising as a tumor imaging agent for positron emission tomography.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Scheme 1
Scheme 2

Similar content being viewed by others

References

  1. Bansode V (2012) Synthesis and evaluation of some coumarin based Schiff’s bases as potential antimicrobial agents. E J Chem 9:2079–2088

    Article  CAS  Google Scholar 

  2. Blum CA (2008) Aminoquinazolines as TRPV1 antagonists: modulation of drug-like properties through the exploration of 2-position substitution. Bioorg Med Chem Lett 18:4573–4577

    Article  CAS  Google Scholar 

  3. Block MH (1992) The aminoquinazoline group as a replacement for the salicylamide group: the design and synthesis of a novel highly selective beta 1 adrenoceptor partial agonist. Drug Des Discov 9:167–176

    CAS  Google Scholar 

  4. Ciardiello F (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053–2063

    CAS  Google Scholar 

  5. Nedergaard MK (2012) Targeting the epidermal growth factor receptor in solid tumor malignancies. Biodrugs 26:83–99

    Article  CAS  Google Scholar 

  6. Stewart JSW (2009) Phase III study of Gefitinib 250 compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 27:3410–3410

    Article  Google Scholar 

  7. Ren X (2005) Research progresses of epidermal growth factor receptor tyrosine kinase inhibitors. Chin J New Drugs 14:821–826

    CAS  Google Scholar 

  8. Gatzemeier U (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545–1552

    Article  CAS  Google Scholar 

  9. Herbst RS (2005) A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892–5899

    Article  CAS  Google Scholar 

  10. Burris HA (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305–5313

    Article  CAS  Google Scholar 

  11. Mei DAI (2009) EGFR-targeted agents in cancer therapy. Chin Bull Life Sci 21:412–417

    Google Scholar 

  12. Castellino S (2012) Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity. Drug Metab Dispos 40:139–150

    Article  CAS  Google Scholar 

  13. Hu S (2012) Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors. Bioorg Med Chem Lett 22:6301–6305

    Article  CAS  Google Scholar 

  14. Minkovsky N (2008) BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs 9:1336–1346

    CAS  Google Scholar 

  15. Tan F (2012) Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 76:177–182

    Article  Google Scholar 

  16. Shi Y (2013) Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 14:953–961

    Article  CAS  Google Scholar 

  17. Tan F (2013) Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): iSAFE study. J Clin Oncol 31:15

    Article  Google Scholar 

  18. Tan F (2015) Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer. Future Oncol 11:385–397

    Article  CAS  Google Scholar 

  19. Bonasera TA (2001) Potential F-18-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. Nucl Med Biol 28:359–374

    Article  CAS  Google Scholar 

  20. Abourbeh G (2007) Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol 34:55–70

    Article  CAS  Google Scholar 

  21. Su H (2008) Evaluation of F-18 gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 35:1089–1099

    Article  CAS  Google Scholar 

  22. Memon AA (2009) Positron emission tomography (PET) imaging with c-11 -labeled erlotinib: a micro-pet study on mice with lung tumor xenografts. Cancer Res 69:873–878

    Article  CAS  Google Scholar 

  23. Tan F (2012) Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 76:177–182

    Article  Google Scholar 

  24. Yang Y (2012) Application status and prospect of domestic drug: icotinib. J Pract Med 28(23):4016–4018

    Google Scholar 

  25. Hu S (2012) Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors. Bioorg Med Chem Lett 22:6301–6305

    Article  CAS  Google Scholar 

  26. Wang, YX (2011) Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof. US20110182882[P]

  27. Zhang S (2010) F-18 labeled benzimidazole derivatives as potential radiotracer for positron emission tomography (PET) tumor imaging. Bioorg Med Chem 18:2394–2401

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We conducted this work with financial support from The National Natural Science Foundation of China (No. 21071022) and the Fundamental Research Funds for the Central Universities. In addition, we would like to thank the cyclotron operator team of the PET center of Xuanwu Hospital for providing the fluoride-18 nuclide.

Author information

Authors and Affiliations

  1. Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, No.19, Xinjiekouwai Street, Haidian District, Beijing, 100875, People’s Republic of China

    Hongyu Ren, Hongyu Ning, Jin Chang, Mingxia Zhao, Yong He, Yan Chong & Chuanmin Qi

Authors
  1. Hongyu Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hongyu Ning
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jin Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mingxia Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong He
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yan Chong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chuanmin Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chuanmin Qi.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 128 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ren, H., Ning, H., Chang, J. et al. Evaluation of 18F-labeled icotinib derivatives as potential PET agents for tumor imaging. J Radioanal Nucl Chem 309, 517–523 (2016). https://doi.org/10.1007/s10967-015-4671-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10967-015-4671-7

Keywords

Search

Navigation